FDA fast track designation supports expedited development and regulatory interaction for BBO-11818 in advanced KRAS-mutant ...

The cancer antigen therapy mRNA-4359 yielded a high rate of antitumor responses in combination with pembrolizumab (Keytruda) ...

Clinical trials show subcutaneous isatuximab is preferred by patients, enabling faster dosing, home treatment, and paving the ...

Liquid biopsy ctDNA reveals targets and flags residual disease in esophageal and gastric cancers, hinting at earlier relapse ...

First patient dosing occurred for JANX011 (NCT07291323), a CD19-targeted bispecific inaugurating the ARM platform to enable ...

Dr. Premal Thaker reports IMNN-001 shows early survival benefit in ovarian cancer by activating immune response directly in ...

Nearly 60% of under-50 cancers are screen-detectable; Ohio State’s BRIDGE program coordinates care, research, and support for ...

In this episode of The OncoloGIST, Dr Christine Bestvina of UChicago Medicine provides a comprehensive look at the rapidly ...

The FDA has granted a priority review to the supplemental Biologics License Application for enfortumab/pembrolizumab to all ...

On-body injector isatuximab enables at-home myeloma treatment, cutting infusion visits, easing time and financial strain, and ...

During a live event, Binod Dhakal, MD, discussed the rationale for choosing therapy given before CAR T-cell infusion in multiple myeloma.

Matthew Powell, MD, discusses long-term overall survival results with dostarlimab plus chemo in dMMR endometrial cancer ...